Scenar Therapy

Development in Taganrog

The manufacturer LET Medical states that Alexander Karasev conceived the idea in 1972 of an 'electrical' form of reflexotherapy that people could use for self-treatment without medication. The manufacturer RITM OKB dates creation of the device to the late 1970s at a design bureau in Taganrog, Russia, names the first prototype ENS-01, and lists five main inventors: Vladislav Zakharevich, Alexander Nechushkin, Alexander Karasev, Alexander Revenko and Alexander Kibirev. Both are companies that sell the devices.

A text attributed to Dr. Alexander Revenko and hosted on a third-party archive gives a physician's account. It says he received an early ENS device from Karasev for clinical trials in 1978, proposed the change from CENAR to SCENAR in 1985, presented the first SCENAR to the USSR Health Care Ministry in 1986, and shared a patent in 1987 with four co-inventors. The text is undated and self-authored. Because the company pages and this account emphasize different people, this article does not name a single inventor.

A space-program origin story

A 2021 trial report states that SCENAR was developed by Soviet space program teams in the 1970s to reduce pain. The two manufacturer history pages and the Revenko account read for this article do not mention a space program, and no independent historical source for the claim was found. It is described here as a claim repeated in one medical paper, not as an established fact.

Expansions of the acronym

SCENAR is expanded in the sources as Self-Controlled Energo-Neuro-Adaptive Regulator, Self-Controlled Electro Neuro Adaptive Regulation and self-controlled energy neuroadaptive regulator, reflecting translation from the Russian acronym. RITM OKB says the first prototype was an energo-neuroadaptive stimulator. A 2023 trial uses 'neuro-adaptive therapy' for treatment given with the device. Spellings and device names therefore vary across the sources reviewed.

Denas and Cosmodic

A Dutch skeptics' organization lists Denas, which it expands as dynamic electro neuro adaptive stimulation, in a family of devices alongside SCENAR. A 2012 Russian review abstract calls dynamic electroneurostimulation (DENS) an electroreflexotherapy modality. LET Medical presents Cosmodic as a third generation after TENS and SCENAR. These are maker or promoter classifications. The sources reviewed contain no independent technical comparison of the devices, so results from SCENAR should not be assumed to apply to Denas or Cosmodic, or the reverse.

How manufacturers describe the device

LET Medical describes devices that apply short-pulse, low-frequency signals through skin contact. On contact the device is said to receive information about the body's state and to form neuron-like impulses meant to restore normal organ function. The company says TENS devices use no feedback, while SCENAR adjusts its signal according to skin impedance and Cosmodic uses many more feedback loops. RITM OKB says constant stimulation leads the body to habituate, whereas SCENAR impulses vary. These are descriptions of a proposed mechanism by sellers, and the trials reviewed here did not test them.

The makers differ on training. RITM OKB says relevant training is recommended for high performance, while a LET Medical page states that special training is not required. The sources reviewed describe no independent professional register or training standard for SCENAR practice.

Sessions as delivered in trials

In a French pain-clinic trial, a 20-minute session began with the handheld device moved over painful areas at 90 Hz with slight pressure, watching for skin redness or pallor and a sensation of the device sticking. Then it was held for 30 to 120 seconds on each flagged zone, with power set to patient comfort. A Russian study gave 8 to 10 sessions of up to 20 minutes, daily for three days and then on alternate days. A Spanish bladder trial used up to eight weekly 20-minute sessions on perineal and sacral skin.

Uses named by manufacturers and promoters

RITM OKB lists musculoskeletal pain, acute and chronic back pain, primary dysmenorrhea, trigeminal neuralgia, diabetic neuropathy, postherpetic neuralgia, headaches and postoperative pain. LET Medical refers more broadly to emergency care, recovery from chronic illness, tissue and organ regeneration, and treatment of various diseases. A skeptics' organization reports promoter claims of up to 70 percent faster recovery across pain, nerve, circulation, joint, respiratory, digestive and gynecological conditions, and notes that these claims are not supported by reliable trials.

Uses studied in the literature

Published reports concern low back and neck pain, overactive bladder, postherpetic neuralgia, duodenal ulcer and spastic cerebral palsy. For the last two, only Russian-language PubMed abstracts were read, so design details are limited to what those abstracts state. How well the maker lists above match the research record is addressed in the next section.

Overall picture

PubMed searches for SCENAR, energoneuroadaptive, Denas, Cosmodic and DiaDENS found no systematic review of SCENAR. The authors of a 2021 trial state that few studies used an accurate methodology and that only two had addressed spinal pain, with conflicting results. Three trials with a comparison group are described below. Reviews of TENS are not applied to SCENAR here.

Low back and neck pain, single session

A French single-center trial randomized 60 adults with low back or neck pain to a 20-minute SCENAR session or an identical session with the device off. Median pain at rest fell from 8 to 5 with the device off and from 7 to 4 with it on, with no significant difference between groups (p = 0.22). Stiffness did not change, the effect had gone by the next day, and adverse effects were minor and similar in both arms. The authors note that sliding the device may itself have a massage-like effect, that some patients felt the current and so may have guessed their group, and that the maker recommends repeated sessions, which were not tested.

Overactive bladder, repeated sessions

A Spanish single-center trial randomized 66 women with urge incontinence not controlled by drugs to SCENAR or a sham in which the device was disconnected. At one month, 23 of 33 (70 percent) in the SCENAR arm met the response definition versus 16 of 33 (48 percent) with sham (p = 0.014), and 55 percent versus 33 percent responded at six months. The authors call it a pilot and note the high sham response. Limits include self-reported outcomes assessed by the two gynecologists who enrolled patients, three dropouts only in the active arm, and a table giving 15 (45 percent) for sham at one month, differing from the text.

Low back pain added to medication

A Russian study of 55 adults with acute or subacute low back pain compared medication alone (30) with medication plus SCENAR (25). Pain scores at the end of treatment were 1.28 versus 3.00 on a 10-point scale. Group allocation used an even-or-odd method, there was no sham, and blinding was not described, so expectation and unequal attention could contribute. The paper's focus was microwave radiometry, and its authors judged conclusions on that method premature.

Adverse events reported

In the pain trial, three patients per arm reported minor effects immediately after the session, such as headache, fatigue or increased stiffness, and eight in total at 24 hours, with none serious. The bladder trial reported no treatment-related complications over six months of follow-up. A Russian study states that SCENAR may cause buzzing, tingling or prickling, that some people may react to electrode materials, and that skin redness may occur. Trials were small and short, and long-term safety has not been studied beyond six months.

Exclusions and cautions

The manufacturer pages read list no contraindications. The trials excluded pregnant or breastfeeding women, people with pacemakers or defibrillators, and skin wounds, recent scars or infection. They also excluded pain linked to inflammatory, traumatic, cancer-related, infectious or neurological causes, and the Russian study excluded gross cardiac arrhythmias. These are eligibility criteria, not a formal contraindication list, and no source read states a rule for application near a malignancy. Pain that is new, severe or persistent needs medical evaluation, and this page does not suggest delaying it.

Skeptical commentary

A skeptics' organization writes that no reliable clinical trials support the device, that the claimed feedback mechanism is unexplained, and that any effect is likely limited to possible pain relief. The French trial authors likewise say high-level publications are lacking and that the TENS-like mechanism is a supposition.

What the record does not show

No independent, replicated, sham-controlled trial for any condition was found among the sources reviewed, and the maker's feedback claims have not been tested in a trial. The two sham-controlled trials reached different conclusions in different conditions, and the positive one was a single-center pilot reported with its own inconsistencies, so the research does not yet allow a general statement about the method.